Hajime Nagasawa, Seiji Ueda, Hitoshi Suzuki, Celia Jenkinson, Yusuke Fukao, Maiko Nakayama, Tomoyuki Otsuka, Teruyuki Okuma, Wilmelenne Clapper, Kai Liu, Mai Nguyen, Radko Komers, Yusuke Suzuki
BACKGROUND: The mechanism leading to the development of IgA nephropathy (IgAN) remains to be completely understood. Endothelin-1 (ET-1) as well as angiotensin II (AngII) promote glomerular injury, tubulointerstitial inflammation, and fibrosis leading to chronic kidney disease. Sparsentan, a dual endothelin angiotensin receptor antagonist (DEARA), recently received accelerated approval in United States for the reduction of proteinuria in adults with IgAN at high risk of disease progression...
January 25, 2024: Nephrology, Dialysis, Transplantation